Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

INCORVAIA, Lorena
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.512
EU - Europa 5.869
AS - Asia 5.248
SA - Sud America 832
AF - Africa 167
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 7
Totale 21.648
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.317
SG - Singapore 2.085
RU - Federazione Russa 1.813
IT - Italia 1.430
CN - Cina 1.148
BR - Brasile 688
DE - Germania 586
HK - Hong Kong 510
VN - Vietnam 478
FI - Finlandia 426
PL - Polonia 387
FR - Francia 264
GB - Regno Unito 250
BD - Bangladesh 242
JP - Giappone 192
UA - Ucraina 152
IN - India 132
IE - Irlanda 131
NL - Olanda 100
CA - Canada 98
KR - Corea 88
SE - Svezia 77
IQ - Iraq 73
MX - Messico 61
TR - Turchia 51
AR - Argentina 49
AT - Austria 46
RO - Romania 46
ZA - Sudafrica 43
ES - Italia 41
BE - Belgio 35
MA - Marocco 28
EC - Ecuador 24
IR - Iran 23
UZ - Uzbekistan 23
PK - Pakistan 21
MY - Malesia 20
AE - Emirati Arabi Uniti 19
CI - Costa d'Avorio 19
ID - Indonesia 19
NP - Nepal 18
EG - Egitto 17
VE - Venezuela 17
KE - Kenya 15
CL - Cile 14
SA - Arabia Saudita 14
PH - Filippine 13
AU - Australia 12
BG - Bulgaria 12
CZ - Repubblica Ceca 12
LT - Lituania 11
PY - Paraguay 11
CO - Colombia 10
TN - Tunisia 10
JM - Giamaica 9
UY - Uruguay 9
CH - Svizzera 8
KZ - Kazakistan 8
PS - Palestinian Territory 8
AZ - Azerbaigian 7
LB - Libano 7
AL - Albania 6
DZ - Algeria 6
JO - Giordania 6
BH - Bahrain 5
BO - Bolivia 5
PA - Panama 5
PE - Perù 5
PT - Portogallo 5
TW - Taiwan 5
CR - Costa Rica 4
CY - Cipro 4
DO - Repubblica Dominicana 4
GR - Grecia 4
ME - Montenegro 4
SN - Senegal 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
BY - Bielorussia 3
DK - Danimarca 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
HU - Ungheria 3
IL - Israele 3
KG - Kirghizistan 3
MD - Moldavia 3
MM - Myanmar 3
NG - Nigeria 3
NI - Nicaragua 3
NO - Norvegia 3
RS - Serbia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
BW - Botswana 2
GH - Ghana 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
LY - Libia 2
Totale 21.616
Salva come PNG Salva come JPEG
Città #
Ashburn 1.327
Singapore 1.293
Fairfield 826
San Jose 650
Chandler 578
Hong Kong 476
Houston 437
Woodbridge 424
Moscow 343
Wilmington 328
Palermo 325
Seattle 318
Zgierz 305
Ann Arbor 278
Cambridge 257
Council Bluffs 221
Los Angeles 220
New York 195
Helsinki 194
Beijing 190
Tokyo 182
Dallas 181
Ho Chi Minh City 163
Rome 163
Hefei 156
The Dalles 153
Lauterbourg 147
Medford 132
Dublin 126
Santa Clara 115
Frankfurt am Main 111
Hanoi 106
Munich 102
Boardman 99
Des Moines 94
Altamura 89
Princeton 87
Buffalo 83
Milan 81
Chicago 77
Jacksonville 75
San Diego 75
Ludwigshafen am Rhein 72
Lawrence 71
São Paulo 62
London 57
Orem 54
Nanjing 51
Seoul 50
Lappeenranta 49
Nuremberg 42
Warsaw 40
Denver 38
Kitzingen 37
Brussels 35
Montreal 35
Atlanta 34
Bremen 34
Dearborn 33
Johannesburg 33
Jinan 31
Redondo Beach 30
Amsterdam 28
Changsha 28
Brooklyn 26
Chennai 26
Haiphong 26
Phoenix 26
Tulsa 26
Guangzhou 24
Naples 24
Stockholm 24
Poplar 22
Rio de Janeiro 22
Baghdad 21
Mexico City 20
Turin 20
Abidjan 19
Tianjin 19
Schiffdorf 18
Tashkent 18
Toronto 18
Vienna 18
Erbil 17
Shanghai 17
Shenyang 17
Turku 17
Boston 16
Memphis 16
Pune 16
Salt Lake City 16
Bari 15
Columbus 15
Falls Church 15
Hải Dương 15
Manchester 15
Nanchang 15
San Francisco 15
Ankara 14
Aversa 14
Totale 13.408
Salva come PNG Salva come JPEG
Nome #
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 351
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 322
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 318
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 301
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 301
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 291
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 283
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 274
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 271
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 266
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 266
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 257
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 253
Liquid Biopsy in Breast Cancer 249
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 247
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 234
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 229
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 228
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 226
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 223
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 223
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 219
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 217
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma 216
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 216
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 211
Serum follistatin in patients with prostate cancer metastatic to the bone 206
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 205
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 204
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 199
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 198
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 198
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 196
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 194
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 190
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 190
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 186
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 184
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 182
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 179
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 177
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 177
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 176
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 176
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 175
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 174
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 174
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 172
Studio del pattern di distribuzione dell'Activina A nel siero di pazienti con metastasi ossee da carcinoma prostatico in trattamento con acido zoledronico 172
Into the wild of long non-coding RNA in gastrointestinal stromal tumors (GISTs) to explore new prognostic/predictive biomarkers 172
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 171
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 171
Liquid Biopsy in Gynecological Cancers 168
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 167
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 162
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge 162
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 159
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 156
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors 154
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 153
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 151
Arterial Stiffness: Effects of Anticancer Drugs Used for Breast Cancer Women 148
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 147
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in metastatic melanoma patients? 147
Liquid Biopsy in Gastrointestinal Stromal Tumor 144
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 143
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 143
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome 143
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 141
Recent advances in desmoid tumor therapy 141
Cancer of the Thyroid 141
The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints 140
Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors 140
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 140
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 139
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 139
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 138
Molecular tumor board 136
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 136
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 134
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 131
Deep Learning Networks for Automatic Retroperitoneal Sarcoma Segmentation in Computerized Tomography 131
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 129
I tumori stromali gastrointestinali: dalla biologia alla clinica 129
Prognostic role of plasma pd‐1, pd‐l1, pan‐btn3as and btn3a1 in patients affected by metastatic gastrointestinal stromal tumors: Can immune checkpoints act as a sentinel for short‐term survival? 129
Current clinically validated applications of liquid biopsy 128
The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies 128
Clinical significance of Activin A serum levels in patients with primary osteoporosis: a preliminary report 125
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 125
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 122
Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices 121
Type and gene location of kit mutations predict progression-free survival to first-line imatinib in gastrointestinal stromal tumors: A look into the exon 121
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 120
Scientific Communication and oncology – "The bridge between knowledge and patients" 119
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 118
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 115
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 111
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 111
Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis 110
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study 109
Totale 18.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.477
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.477
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202199 0 0 0 0 0 0 0 0 0 0 0 99
2021/20221.264 87 186 59 28 53 70 55 69 113 162 166 216
2022/20231.686 170 306 37 217 160 245 91 143 169 33 75 40
2023/20241.184 43 127 104 112 76 181 145 122 24 65 21 164
2024/20253.414 117 153 140 267 151 232 417 283 243 410 417 584
2025/202610.855 854 332 770 981 1.196 1.586 1.512 1.015 860 814 601 334
Totale 22.536